Jefferies Group LLC Glycomimetics Inc Transaction History

Jefferies Group LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2019 Feb 13, 2020	SELL	$4.03 - $6.5 $126,147 - $203,463	-31,302 Closed	0 $0
Q3 2019 Nov 13, 2019	BUY	$2.8 - $12.85 $87,645 - $402,230	31,302 New	31,302 $135,000
Q2 2019 Aug 14, 2019	SELL	$10.6 - $13.12 $631,813 - $782,017	-59,605 Closed	0 $0
Q1 2019 May 15, 2019	BUY	$9.96 - $13.44 $216,789 - $292,535	21,766 Added 57.52%	59,605 $743,000
Q4 2018 Feb 14, 2019	SELL	$8.47 - $14.71 $1.13 Million - $1.95 Million	-132,856 Reduced 77.83%	37,839 $358,000
Q3 2018 Nov 14, 2018	BUY	$13.7 - $17.12 $2.34 Million - $2.92 Million	170,695 New	170,695 $2.46 Million
Q1 2018 May 15, 2018	SELL	$16.06 - $25.35 $865,136 - $1.37 Million	-53,869 Closed	0 $0
Q4 2017 Feb 14, 2018	BUY	$10.51 - $17.22 $566,163 - $927,624	53,869	53,869 $904,000

17.8M

Ticker GLYC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,423,900
Market Cap $16.8M
Description
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in the United States. It is developing uproleselan, an E-selectin inhibitor, which is used in combination with chemotherapy to treat acute myeloid leukemia (AML),...

Get notified when there are updates to the investment portfolio of Jefferies Group LLC, based on Form 13F filings with the SEC.

Stay updated on Jefferies Group LLC with notifications on news.